Key statistics
As of last trade Vaxcyte Inc (5VA:DUS) traded at 86.50, -19.91% below its 52-week high of 108.00, set on Oct 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 80.00 |
---|---|
High | 86.50 |
Low | 80.00 |
Bid | 84.00 |
Offer | 85.50 |
Previous close | 80.50 |
Average volume | 7.67 |
---|---|
Shares outstanding | 124.64m |
Free float | 121.98m |
P/E (TTM) | -- |
Market cap | 10.71bn USD |
EPS (TTM) | -4.55 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 18:31 GMT.
More ▼
Announcements
- Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
- Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
- Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte Announces Pricing of $1.3 Billion Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte Appoints John Furey to Board of Directors
More ▼